Patrick D. Lamy

Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women

Characterization of a canine homolog of hepatitis C virus

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Management of hepatitis B

A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

Viral RNA Induces Type I Interferon-Dependent Cytokine Release and Cell Death in Mesangial Cells via Melanoma-Differentiation-Associated Gene-5

A placebo‐controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection

Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir

Hepatitis B Virus Infection — Natural History and Clinical Consequences

Clinical and Biological Evolution of HIV-1 Seroconverters in Abidjan, Côte d'Ivoire, 1997–2000

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B

HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo

Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013

Incidence and impact of resistance against approved antiretroviral drugs

A robust cell culture system supporting the complete life cycle of hepatitis B virus

Enrollment Characteristics and Risk Behaviors of Injection Drug Users Participating in the Bangkok Tenofovir Study, Thailand

Factors Associated with the Emergence of K65R in Patients with HIV‐1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir

Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline

Management of hepatitis B: 2000—Summary of a workshop

Viral Infection in the Renal Transplant Recipient

Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update*

Viral nephropathy

COVID-19: A promising cure for the global panic

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

Hepatitis B virus infection

Chronic hepatitis B

Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

Adefovir dipivoxil: A new antiviral agent for the treatment of hepatitis B virus infection

Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model

Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease

Zidovudine and Stavudine Sequencing in HIV Treatment Planning: Findings From the CHORUS HIV Cohort

Diagnosis, management, and treatment of hepatitis C: An update # † ‡

Management of chronic viral hepatitis before and after renal transplantation

Treatment of chronic hepatitis B

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma

Aerosol Generating Procedures and Risk of Transmission of Acute Respiratory Infections to Healthcare Workers: A Systematic Review

Management of Hepatocellular Carcinoma *

Viral hepatitis B

The role of sexually transmitted diseases in HIV transmission

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

Priming of hepatitis C virus-specific cytotoxic t lymphocytes in mice following portal vein injection of a liver-specific plasmid DNA

Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level

Chronic hepatitis B

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

Chemoprophylaxis with Tenofovir Disoproxil Fumarate Provided Partial Protection against Infection with Simian Human Immunodeficiency Virus in Macaques Given Multiple Virus Challenges

Chronic hepatitis B: Update 2009 #

Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B

Effect of Tenofovir Disoproxil Fumarate on the Pharmacokinetics and Pharmacodynamics of Total, R‐, and S‐Methadone

Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy†

Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy

Systematic Review and Meta‐analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV‐Infected Patients

Microbicides and HIV prevention: lessons from the past, looking to the future

Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer

Genomic Analysis Reveals a Potential Role for Cell Cycle Perturbation in HCV-Mediated Apoptosis of Cultured Hepatocytes

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

Inhibition of HIV replication: A powerful antiviral strategy by IFN-β gene delivery in CD4+ cells

Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA

Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy

Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens

Hepatocellular carcinoma pathogenesis: from genes to environment

Infection in Solid-Organ Transplant Recipients

Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

Evaluating Medication Effects Outside of Clinical Trials: New-User Designs

Antiretroviral Treatment of Adult HIV Infection

Herpes Zoster

Hepatitis B virus induces RNR-R2 expression via DNA damage response activation

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus

Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir

Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients<SUBTITLE>A 3-Year Randomized Trial</SUBTITLE>

Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals

Steady‐State Pharmacokinetics of Emtricitabine and Tenofovir Disoproxil Fumarate Administered Alone and in Combination in Healthy Volunteers

Liver transplantation for hepatitis B virus-related liver disease: Indications, prevention of recurrence and results

HIV-1 Neutralization Profile and Plant-Based Recombinant Expression of Actinohivin, an Env Glycan-Specific Lectin Devoid of T-Cell Mitogenic Activity

Evaluation of antiretrovirals in animal models of HIV infection

Stem cell-derived polarized hepatocytes

Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial

Chronic Hepatitis B: Current Testing Strategies

Antiretroviral Therapy in Adults

Memory CD4 ⁺ T Cells Are the Earliest Detectable Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Cells in the Female Genital Mucosal Tissue during HIV-1 Transmission in an Organ Culture System

MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments

Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America

Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus

Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy

Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective

2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings

Efficacy of Postexposure Prophylaxis after Intravaginal Exposure of Pig-Tailed Macaques to a Human-Derived Retrovirus (Human Immunodeficiency Virus Type 2)

Review of solid-organ transplantation in HIV-infected patients

High Levels of Viral Replication Contrast with Only Transient Changes in CD4⁺and CD8⁺Cell Numbers during the Early Phase of Experimental Infection with Simian Immunodeficiency Virus SIVmnd-1 inMandrillus sphinx

EASL Recommendations on Treatment of Hepatitis C 2018

Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus

Zidovudine and Stavudine Sequencing in HIV Treatment Planning: Findings From the CHORUS HIV Cohort

Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient

Inhibitory Effect of Adefovir on Viral DNA Synthesis and Covalently Closed Circular DNA Formation in Duck Hepatitis B Virus-Infected Hepatocytes In Vivo and In Vitro

Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus

Prevention of Hepatitis B Recurrence after Liver Transplantation

Treatment of Chronic Viral Hepatitis

The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace

In Vitro Susceptibilities of Wild-Type or Drug-Resistant Hepatitis B Virus to (−)-β-d-2,6-Diaminopurine Dioxolane and 2′-Fluoro-5-Methyl-β-l-Arabinofuranosyluracil

Adefovir and Tenofovir Susceptibilities of HIV-1 After 24 to 48 Weeks of Adefovir Dipivoxil Therapy: Genotypic and Phenotypic Analyses of Study GS-96-408

Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals

The Safety and Efficacy of Adefovir Dipivoxil, a Novel Anti‐Human Immunodeficiency Virus (HIV) Therapy, in HIV‐Infected Adults: A Randomized, Double‐Blind, Placebo‐Controlled Trial

Human Immunodeficiency Virus Type 1 Expressing the Lamivudine‐Associated M184V Mutation in Reverse Transcriptase Shows Increased Susceptibility to Adefovir and Decreased Replication Capability In Vitro

Human Immunodeficiency Virus Type 1 Reverse Transcriptase Expressing the K70E Mutation Exhibits a Decrease in Specific Activity and Processivity

In Vitro Antiviral Susceptibilities of Isolates from Cytomegalovirus Retinitis Patients Receiving First‐ or Second‐Line Cidofovir Therapy: Relationship to Clinical Outcome

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

FULMINANT HEPATIC FAILURE RESULTING FROM LAMIVUDINE-RESISTANT HEPATITIS B VIRUS IN A RENAL TRANSPLANT RECIPIENT

Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from AIDS Patients after Prolonged Adefovir Dipivoxil Therapy

Early Short-Term 9-[2-( R )-(Phosphonomethoxy)Propyl]Adenine Treatment Favorably Alters the Subsequent Disease Course in Simian Immunodeficiency Virus-Infected Newborn Rhesus Macaques

Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults

9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) Therapy Prolongs Survival of Infant Macaques Inoculated with Simian Immunodeficiency Virus with Reduced Susceptibility to PMPA

In vitro Selection and Characterization of HIV-1 with Reduced Susceptibility to PMPA